SCHEMBL6433952

SCHEMBL6433952

COC(=O)C1(S(=O)(=O)N2CCC(c3ccc(-c4cccc(OCCOC(C)(C)C)n4)c(C)c3)CC2)CCOCC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 13/20 0.57
MMP3 P08254 9/20 0.57
MMP9 P14780 5/20 0.57
MMP1 P03956 2/20 0.57
MMP14 P50281 2/20 0.57
MMP13 P45452 3/20 0.33
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
PKM P14618 1/20 0.32
CYP2C19 P33261 1/20 0.32
ADAM10 O14672 4/20 0.32
GUCY1A1 Q02108 2/20 0.32
GUCY1B1 Q02153 2/20 0.32
HTR1A P08908 1/20 0.31
DRD2 P14416 1/20 0.31
DRD4 P21917 1/20 0.31
TLR9 Q9NR96 1/20 0.31
GLP1R P43220 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6434450 0.93 MMP2 (0.56) MMP2MMP3MMP9MMP1MMP14
SCHEMBL6434543 0.92 MMP2 (0.60) MMP2MMP3MMP9MMP1MMP14
SCHEMBL6433286 0.92 MMP2 (0.64) MMP2MMP3MMP9MMP1MMP14
SCHEMBL6965123 0.89 MMP2 (0.55) MMP2MMP3MMP9MMP1MMP14
SCHEMBL6433456 0.89 MMP2 (0.55) MMP2MMP3MMP9MMP1MMP14
SCHEMBL6433803 0.86 MMP2 (0.52) MMP2MMP3MMP9MMP1MMP14
SCHEMBL6433657 0.86 MMP2 (0.52) MMP2MMP3MMP9MMP1MMP14
SCHEMBL6972044 0.84 MMP2 (0.50) MMP2MMP3MMP9MMP1MMP14
SCHEMBL7586454 0.84 MMP2 (0.50) MMP2MMP3MMP9MMP1MMP14
SCHEMBL6436660 0.84 MMP2 (0.50) MMP2MMP3MMP9MMP1MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1181017-B1 METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-04-16 EP claimed
US-6511993-B1 Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes PFIZER INC. 2003-01-28 US claimed
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1181017-B1 METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-04-16 EP disclosed
US-6511993-B1 Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes PFIZER INC. 2003-01-28 US disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MMP2 19/4885MMP3 28/4885MMP9 44/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MMP2 19/4885MMP3 28/4885MMP9 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.